BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19936766)

  • 1. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer.
    Schimanski CC; Zimmermann T; Schmidtmann I; Gockel I; Lang H; Galle PR; Moehler M; Berger MR
    Int J Colorectal Dis; 2010 Feb; 25(2):181-6. PubMed ID: 19936766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.
    Gockel I; Moehler M; Frerichs K; Drescher D; Trinh TT; Duenschede F; Borschitz T; Schimanski K; Biesterfeld S; Herzer K; Galle PR; Lang H; Junginger T; Schimanski CC
    Oncol Rep; 2008 Oct; 20(4):845-50. PubMed ID: 18813825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer.
    Schimanski CC; Moehler M; Gockel I; Zimmermann T; Lang H; Galle PR; Berger MR
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1139-45. PubMed ID: 21468700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia.
    Zahrani A; Kandil M; Badar T; Abdelsalam M; Al-Faiar A; Ismail A
    Tumori; 2014; 100(1):75-9. PubMed ID: 24675495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does expression of receptor tyrosine kinases in gastric adenocarcinoma correlate with clinicopathological parameters?
    Drescher D; Gockel I; Timm S; Berger MR; Herzer K; Schmidtmann I; Junginger T; Galle PR; Lang H; Moehler M; Schimanski CC
    Hepatogastroenterology; 2010; 57(98):388-94. PubMed ID: 20583450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulated PDGFR alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size.
    Ben Jemii N; Tounsi-Kettiti H; Yaiche H; Mezghanni N; Jaballah Gabteni A; Fehri E; Ben Fayala C; Abdelhak S; Boubaker S
    J Transl Med; 2020 Nov; 18(1):440. PubMed ID: 33213472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of annexin A1 is correlated with K-ras mutation in colorectal cancer.
    Su N; Xu XY; Chen H; Gao WC; Ruan CP; Wang Q; Sun YP
    Tohoku J Exp Med; 2010 Dec; 222(4):243-50. PubMed ID: 21127395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
    Nasir A; Reising LO; Nedderman DM; Fulford AD; Uhlik MT; Benjamin LE; Schade AE; Holzer TR
    Anticancer Res; 2016 Jun; 36(6):2683-96. PubMed ID: 27272777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
    Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
    Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
    Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
    Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
    Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
    BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.
    Pérez-Ruiz E; Rueda A; Pereda T; Alcaide J; Bautista D; Rivas-Ruiz F; Villatoro R; Pérez D; Redondo M
    Tumour Biol; 2012 Dec; 33(6):1829-35. PubMed ID: 22791568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer.
    Laczmanska I; Karpinski P; Kozlowska J; Bebenek M; Ramsey D; Sedziak T; Ziolkowski P; Sasiadek MM
    Pathol Res Pract; 2014 Dec; 210(12):893-6. PubMed ID: 25169130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma.
    Al-Allawi NA; Ismaeel AT; Ahmed NY; Merza NS
    Indian J Cancer; 2012; 49(1):163-8. PubMed ID: 22842183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.